Bio-Techne Corp (TECH)

Receivables turnover

Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020
Revenue (ttm) US$ in thousands 1,219,634 1,208,768 1,196,015 1,171,582 1,159,059 1,154,281 1,144,999 1,143,982 1,136,702 1,123,611 1,119,841 1,117,536 1,105,600 1,076,399 1,029,575 984,552 931,032 847,838 798,966 759,647
Receivables US$ in thousands 206,876 237,140 217,940 223,688 241,394 227,887 207,451 204,570 218,468 216,415 184,763 174,174 194,548 202,095 152,896 147,548 145,385 157,790 128,243 122,635
Receivables turnover 5.90 5.10 5.49 5.24 4.80 5.07 5.52 5.59 5.20 5.19 6.06 6.42 5.68 5.33 6.73 6.67 6.40 5.37 6.23 6.19

June 30, 2025 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,219,634K ÷ $206,876K
= 5.90

The receivables turnover ratio for Bio-Techne Corp exhibits a pattern of fluctuation over the analyzed period. Starting with a ratio of 6.19 as of September 30, 2020, the metric shows slight increases and decreases over subsequent quarters, with notable peaks occurring at 6.73 in December 2021 and reaching a high of 6.67 in September 2021. Conversely, periods such as March 2022 and March 2024 reflect lower ratios of approximately 5.33 and 5.07, respectively. The ratio demonstrates a general tendency for modest oscillations, fluctuating between approximately 4.80 and 6.73 throughout the period.

From a comparative perspective, the overall trend indicates relative consistency with median ratios hovering around 5.4 to 6.7, suggesting a stable and efficient receivables collection process with occasional improvements or slight setbacks. The downward trend observed at certain points, particularly from March 2022 onward, may imply periods of slower collections or increased credit extended to customers, whereas the intermittent increases reflect periods of more rapid receivables turnover.

These variations, while maintaining an overall stable range, highlight the company's routine management of receivables collection and credit policies. Evaluating this data implies that Bio-Techne Corp's receivables turnover remains within a consistent operational bandwidth, revealing neither definitive signs of deterioration nor significant improvements in receivables management over the analyzed timeframe.